MAM
BOLT icon

Marquette Asset Management’s Bolt Biotherapeutics BOLT Stock Holding History

Marquette Asset Management’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,690
Closed -$85.3K – 236
2024
Q2 		$85.3K Buy
5,690
+856
+18% +$16.9K 0.01% 119
2024
Q1 		$135K Hold
4,834
– – 0.02% 92
2023
Q4 		$108K Sell
4,834
-58
-1% -$1.13K 0.02% 101
2023
Q3 		$102K Hold
4,892
– – 0.02% 102
2023
Q2 		$125K Hold
4,892
– – 0.03% 99
2023
Q1 		$136K Hold
4,892
– – 0.04% 98
2022
Q4 		$127K Buy
4,892
+1,703
+53% +$46.7K 0.04% 97
2022
Q3 		$94K Hold
3,189
– – 0.03% 111
2022
Q2 		$130K Buy
+3,189
New +$124K 0.04% 109

Other funds holding BOLT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Marquette Asset Management's BOLT Position: Q3 2024 in Review

Marquette Asset Management sold out of Bolt Biotherapeutics (BOLT) in Q3 2024, closing a stake of 5,690 shares — an estimated $85.3K sold.

Marquette Asset Management first reported a position in BOLT in Q2 2022 and held it in 9 quarters. The position peaked at $136K in Q1 2023. 32 funds tracked by Wall St. Rank hold BOLT as of Q3 2024.

  • Marquette Asset Management reported no remaining Bolt Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Marquette Asset Management sold 5,690 Bolt Biotherapeutics shares in Q3 2024, an estimated $85.3K.
  • Marquette Asset Management first reported a position in Bolt Biotherapeutics in Q2 2022 and held it in 9 quarters.
  • Marquette Asset Management's Bolt Biotherapeutics position peaked at $136K in Q1 2023.
  • 32 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q3 2024.

Based on Marquette Asset Management's 13F filing for Q3 2024, filed 8 Oct 2024.